Roche announced today it has licensed its P2X31 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.
Interested in Monitoring? Call 877-596-2224
Current Customers Call 877-296-6465
Patients & Other Questions Call 877-643-6179